Program
AZD0240
A development code. Also written as “AZD0240: Autologous, engineered T Cells targeting KRAS G12D”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by AstraZeneca.
Furthest: phase 1, since Jan 9, 20241 company-led study, 1 open or runningNext primary completion: Aug 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 1since Jan 9, 2024 | Jan 9, 2024 | Aug 30, 2027phase 1 · NCT06218914 |
- Named in AstraZeneca’s own pipeline as
AZD0240
, phase 1, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06218914 · 108 enrolled · United States
Ahead
- Aug 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06218914
TargetBeta
“AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02”study text, read by Claude · the study
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06218914Carcinoma, Non-Small-Cell Lung · United States | 1 | Active, not recruiting | Aug 30, 2027 | 108 |
How it is read
Names in the registry
- “AZD0240: Autologous, engineered T Cells targeting KRAS G12D”, 1 entry
Codes read as this program: AZD0240.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.